Light Therapy in Modulating the Clinical Phenotype of Patients With Primary and Comorbid Chronic Insomnia.

Insomnia Chronic Clinical Trial

— Luminoterapia  

Official title:

Multicenter Study on the Role of Light Therapy in Modulating the Clinical Phenotype of Patients With Primary and Comorbid Chronic Insomnia Through Circadian Phase Modification.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05797324
• Other study ID #: 21A011
• Status: Recruiting
• Phase: N/A
• Start date: November 17, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: April 2023
• Source: Istituto Auxologico Italiano
• Contact: Riccardo Cremascoli
• Phone: +393497292068
• Email: r.cremascoli[@]auxologico.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Some evidence indicates that circadian rhythm may play a role in the pathophysiology of insomnia disorder. This single-blind randomized controlled multicentre prospective study aims to evaluate the possible therapeutic effect of light therapy in modulating the clinical phenotype of patients affected by chronic primary and comorbid insomnia, through the modification of the circadian phase.

Description:

Some evidence indicates that circadian rhythm may play a role in the pathophysiology of insomnia disorder. This single-blind randomized controlled multicentre prospective study aims to evaluate the possible therapeutic effect of light therapy in modulating the clinical phenotype of patients affected by chronic primary and comorbid insomnia, through the modification of the circadian phase.

STUDY DESIGN AND METHODS

With regard to the study in question, it should be noted that:

• the study is a prospective multicentre randomized single-blind controlled trial

• the duration of the study is expected to be 3 years with a duration of enrollment of 2 and a half years and a minimum clinical follow-up of 3 months

The study will be divided into two evaluations, an initial evaluation (Time 0, T0) where the patients will be enrolled and all the measurements required before treatment with light therapy will be performed, and a final evaluation after 6 weeks of treatment with light therapy effective or sham (Time 1, T1), where the measurements performed at T0 will be repeated. Both assessments will be performed at the Sleep Medicine outpatient clinic.

TIME T0

• The diagnosis of primary chronic or comorbid insomnia will be made during the semi-structured sleep interview by a physician expert in sleep medicine, according to DSM V criteria, supported by clinical scales (Insomnia Severity Index, Pittsburgh Quality Index). The presence of mood/behavioral disorders or cognitive deficits will also be excluded (Beck, Stai, Mini Mental Scale Examination).

• A home polysomnography will be performed to rule out the presence of sleep apnea disorder or periodic limb movement syndrome during sleep

• Circadian parameters (chronotype, Mid sleep, circadian phase, phase angle) will be evaluated in basal conditions through clinical scales (Morning Eveningness Questionnaire, Light diet), measurement of salivary melatonin using evening 5-point wipes at home (DLMO, Elisa) and the actigraphic registration extended for 7 days.

• The associations between the circadian phase and the various phenotypes of primary or comorbid insomnia will be then evaluated, according to the duration and the severity of insomnia.

• Patients without ocular contraindications will then undergo a Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian phase, or sham treatment (control subgroup; white light <100 lux equivalent).

• Patients will be randomly assigned to one of two conditions (treatment and sham). The randomization list will be generated with a simple randomization method through the use of a "Random number generator" software available at www.regione.emilia-romagna.t/sin_info/generatore. The algorithm used in this site coincides with a Lehmer generator (multiplicative congruential generator). Allocation concealment is guaranteed by a central randomization in a distant and independent location with respect to the recruitment site.

TIME T1

> After 6 consecutive weeks of home light therapy, patients will be re-evaluated with the same somnometry battery used at study entry. Furthermore, the actigraphic monitoring and the dosage of salivary melatonin will be repeated, to evaluate the variations of the circadian phase and of the sleep-wake pattern after light therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Primary chronic insomnia

• Comorbid chronic insomnia

• Absence of pharmacological therapy of insomnia

• Absence of behavioural and cognitive treatment of insomnia

• Capacity to understand the study and adhere to the procedures

• Written informed consent

Exclusion Criteria:

• Secondary insomnia due to medical conditions or drug treatment

• Cerebral diseases

• Invalidating diseases

• Eye diseases that contraindicate the use of light therapy

• Psychiatric disorders

• Cognitive decline

• Working in night shifts during the last month before enrolment

• Impossibility to provide informed consent

Related Conditions & MeSH terms

• Insomnia Chronic
• Sleep Initiation and Maintenance Disorders

Intervention

Other:
• Luminette
Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
• Sham
Sham protocol (white light <100 lux equivalent).

Locations

Country	Name	City	State
Italy	Istituto Auxologico Italiano	Oggebbio

Sponsors (3)

Lead Sponsor	Collaborator
Istituto Auxologico Italiano	Ente Ospedaliero Cantonale, Ticino, Switzerland, IRCCS National Neurological Institute "C. Mondino" Foundation

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Insomnia Severity Index	Insomnia Severity Index (ISI, Pittsburgh Quality Index) - self-report questionnaire composed of 19 items assessing sleep quality	Baseline and after 6 weeks of intervention
Secondary	Change in salivary melatonin	Salivary melatonin - evening 5-point wipes (DLMO, Elisa)	Baseline and after 6 weeks of intervention